GENI.L Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 11:38):

Stats
Dagens volum	92 180.00
Gjennomsnittsvolum	366 983
Markedsverdi	12.67M
EPS	£0 ( 2023-09-20 )
Neste inntjeningsdato	( £0 ) 2024-06-04
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.190
ATR14	£0.202 (2.82%)

GENinCode plc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

GENinCode plc Økonomi

Annual	2022
Omsetning:	£1.43M
Bruttogevinst:	£632 000 (44.20 %)
EPS:	£-0.0580

FY	2022
Omsetning:	£1.43M
Bruttogevinst:	£632 000 (44.20 %)
EPS:	£-0.0580

FY	2021
Omsetning:	£1.15M
Bruttogevinst:	£593 000 (51.39 %)
EPS:	£-0.0432

FY	2020
Omsetning:	£960 801
Bruttogevinst:	£523 016 (54.44 %)
EPS:	£-0.0111

Financial Reports:

No articles found.

GENinCode plc

GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test, which analyzes the seven genes associated with familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test that analyzes 12 genetic variants related to hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Oxford, the United Kingdom.